Abstract:Background: Parkinson's disease (PD) is a movement disorder characterized by the progressive loss of dopamine neurons. Microglia-mediated neuroinflammation drives disease progression and becomes a critical factor in neuronal degeneration. Recent studies have found that nuclear factor-erythroid 2-related-2 (Nrf2) expression levels are reduced during aging and neurodegenerative diseases, but its regulatory mechanism on microglia-induced neuroinflammation has not been fully elucidated. Methods: In vivo, we used the intraperitoneal injection of the neurotoxic drug neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to establish an animal model of PD and, at the same time, administered Nrf2 inhibitors ML385 and dimethyl fumarate to regulate Nrf2 protein levels. In vitro, we used si-RNA to knock out the Nrf2 gene to intervene in BV2 cells and used lipopolysaccharide (LPS) to stimulate and induce the cell model. Results: The study found that inhibition of Nrf2 expression aggravated the motor defects of PD mice, accompanied by a significant loss of dopaminergic neurons in the substantia nigra and striatum of the brain. In addition, after inhibition of Nrf2, the malondialdehyde (MDA) level in the substantia nigra of the midbrain of mice increased, and the levels of superoxide dismutase (SOD) and heme oxygenase-1 (HO-1) decreased, accompanied by the proliferation of microglia and astrocytes. In addition, the activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, the assembly of apoptosis-associated speck-like protein containing a CARD (ASC) protein in microglia, and the release of downstream inflammatory factors caspase-1 and interleukin (IL)-1β, were aggravated. At the cellular level, it was found that knocking out the expression of Nrf2 would aggravate the activation of NLRP3 inflammasomes and the assembly of ASC in LPS-induced BV2 cells. Conclusion: Inhibited Nrf2 activity can reduce the downstream antioxidant enzyme HO-1 and antioxidant levels, induce NLRP3 inflammasome activation and ASC protein assembly in microglia, and ultimately aggravate PD inflammatory response and dopamine neuron degeneration.

Inhibition of Abnormal C/EBPβ/α‐Syn Signaling Pathway Through Activation of Nrf2 Ameliorates Parkinson's Disease‐like Pathology

NFE2L2 variations reduce antioxidant response in patients with Parkinson disease.

Nrf2 Inhibits the Progression of Parkinson's Disease by Upregulating AABR07032261.5 to Repress Pyroptosis

Suppression of Abnormal Α-Synuclein Expression by Activation of BDNF Transcription Ameliorates Parkinson's Disease-Like Pathology.

C/EBPβ/δ-secretase Signaling Mediates Parkinson's Disease Pathogenesis Via Regulating Transcription and Proteolytic Cleavage of Α-Synuclein and MAOB.

C/EBPβ/δ-secretase signaling mediates Parkinson’s disease pathogenesis via regulating transcription and proteolytic cleavage of α-synuclein and MAOB

Nrf2 as a potential target for Parkinson’s disease therapy

Regulation of BDNF Transcription by Nrf2 and MeCP2 Ameliorates MPTP-induced Neurotoxicity

PAR2-mediated epigenetic upregulation of α-synuclein contributes to the pathogenesis of Parkinson׳s disease.

Tetramethylpyrazine Nitrone Promotes the Clearance of Alpha-Synuclein via Nrf2-Mediated Ubiquitin–Proteasome System Activation

PDCD4 Triggers Α-Synuclein Accumulation and Motor Deficits Via Co-Suppressing TFE3 and TFEB Translation in a Model of Parkinson’s Disease

Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects

Tetramethylpyrazine Nitrone Exerts Neuroprotection Via Activation of PGC-1α/Nrf2 Pathway in Parkinson's Disease Models.

Inhibition of EHMT1/2 rescues synaptic damage and motor impairment in a PD mouse model

Nrf2 Deficiency Exacerbates Parkinson's Disease by Aggravating NLRP3 Inflammasome Activation in MPTP-Induced Mouse Models and LPS-Induced BV2 Cells

Tetramethylpyrazine nitrone exerts neuroprotection via PGC-1α/Nrf2 activation and α-synuclein clearance in Parkinson’s disease models

C/EBPβ/AEP is Age-Dependently Activated in Parkinson’s Disease and Mediates Α-Synuclein in the Gut and Brain

Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease

Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease

Alpha-synuclein Fibrils Inhibit Activation of the BDNF/ERK Signaling Loop in the mPFC to Induce Parkinson's Disease-like Alterations with Depression

Baicalin Represses C/EBPβ Via Its Antioxidative Effect in Parkinson’s Disease